Hiya, I see other replies to your Q already. Here is the info I posted about Lumos-Diasorin ann in the Media thread:=> Post #: 52306043
It doesn't impact AT1-FebriDx test supply in any way. It does make LumosDx a stronger company with an new channel for cashflow via its OEM assay dev biz.
Which is good for AT1 if its partners grow stronger, have good amts of cash to put into FebriDx expansion + any future test dev collaborations.
AT1 FY21 - General Discussion + FA, page-1185
-
- There are more pages in this discussion • 1,249 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
